---
figid: PMC9297058__12325_2022_2246_Fig1_HTML
figtitle: 'Brain Abnormalities in PIK3CA-Related Overgrowth Spectrum: Physician, Patient,
  and Caregiver Experiences'
organisms:
- Homo sapiens
- Syzygium aromaticum
pmcid: PMC9297058
filename: 12325_2022_2246_Fig1_HTML.jpg
figlink: /pmc/articles/PMC9297058/figure/Fig1/
number: F1
caption: PI3K signaling pathway. Gain of function mutations in PIK3CA result in increased
  PI3Kα activity, leading to abnormal cell function. Several drugs that target proteins
  in this pathway are being investigated for use in treating PROS disorders, including
  sirolimus (mTOR), miransertib (AKT), and alpelisib (PI3Kα). AKT protein kinase B,
  CDC42 cell division control protein 42 homolog, mTOR mammalian target of rapamycin,
  PI3K phosphatidylinositol-3-kinase, PI3Kα phosphatidylinositol-3-kinase catalytic
  subunit alpha, PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit
  alpha, PKC protein kinase C, PROS PIK3CA-related overgrowth spectrum, PTEN phosphatase
  and tensin homolog, RAC1 Ras-related C3 botulinum toxin substrate 1, SGK serum-
  and glucocorticoid-inducible kinase. Reprinted from Canaud et al. []. Licensed under
  a Creative Commons Attribution 4.0 International License, https://creativecommons.org/licenses/by/4.0/
papertitle: 'Brain Abnormalities in PIK3CA-Related Overgrowth Spectrum: Physician,
  Patient, and Caregiver Experiences.'
reftext: Joy Dexheimer, et al. Adv Ther. 2022 Jul 20 ;39(9):3871-3880.
year: '2022'
doi: 10.1007/s12325-022-02246-7
journal_title: Advances in Therapy
journal_nlm_ta: Adv Ther
publisher_name: Springer Healthcare
keywords: Megalencephaly-capillary malformation | Mosaicism | PIK3CA | PI3K | PROS
automl_pathway: 0.9267876
figid_alias: PMC9297058__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC9297058__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9297058__12325_2022_2246_Fig1_HTML.html
  '@type': Dataset
  description: PI3K signaling pathway. Gain of function mutations in PIK3CA result
    in increased PI3Kα activity, leading to abnormal cell function. Several drugs
    that target proteins in this pathway are being investigated for use in treating
    PROS disorders, including sirolimus (mTOR), miransertib (AKT), and alpelisib (PI3Kα).
    AKT protein kinase B, CDC42 cell division control protein 42 homolog, mTOR mammalian
    target of rapamycin, PI3K phosphatidylinositol-3-kinase, PI3Kα phosphatidylinositol-3-kinase
    catalytic subunit alpha, PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase
    catalytic subunit alpha, PKC protein kinase C, PROS PIK3CA-related overgrowth
    spectrum, PTEN phosphatase and tensin homolog, RAC1 Ras-related C3 botulinum toxin
    substrate 1, SGK serum- and glucocorticoid-inducible kinase. Reprinted from Canaud
    et al. []. Licensed under a Creative Commons Attribution 4.0 International License,
    https://creativecommons.org/licenses/by/4.0/
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SGK1
  - RAC1
  - RNASE1
  - CDC42
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - MTOR
---
